Arcus Biosciences Inc (RCUS) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NYSE

Key Metrics

• Price: $19.54
• Market Cap: $2.51B
• EPS: $-3.42
• 52-Week High: $26.40
• 52-Week Low: $6.50

Market Sentiment

Arcus Biosciences Inc currently has a Bullish sentiment score of 0.15.

About Arcus Biosciences Inc

Arcus Biosciences, Inc. (RCUS) is a clinical-stage biopharmaceutical company headquartered in Hayward, California, dedicated to revolutionizing cancer treatment through its innovative pipeline of immune-oncology and targeted therapies. The company leverages proprietary platforms and strategic collaborations to develop cutting-edge therapies aimed at empowering the immune system to combat tumors. With a strong commitment to improving patient outcomes, Arcus is uniquely positioned for substanti...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Arcus Biosciences Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does RCUS pay dividends?

Arcus Biosciences Inc (RCUS) does not currently pay a regular dividend.

What is RCUS's market cap?

Arcus Biosciences Inc (RCUS) has a market capitalization of $2.51B with a current stock price of $19.54.